← 返回

人 ILC2 的分离、扩增及过继转移用于治疗荷液体瘤和实体瘤小鼠

英文原题:Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors.

查看英文原题

Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumors.

PubMed 2024/07/31(内容时间) STAR Protoc Q4 · IF 1.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

2型固有淋巴细胞(ILC2s)在调节免疫反应和多种生理过程中至关重要,包括组织修复、代谢稳态、炎症和肿瘤监视。在此,我们提出了一种方案,概述了从外周血单个核细胞中分离、扩增和过继转移人ILC2s,用于小鼠模型中的体内谱系追踪实验。此外,我们详细描述了将人ILC2s过继转移至携带人血液肿瘤或实体瘤的受体小鼠的步骤。关于本方案使用和执行的完整细节,请参阅Li等人1。

展开英文摘要原文

Type 2 innate lymphoid cells (ILC2s) are crucial in regulating immune responses and various physiological processes, including tissue repair, metabolic homeostasis, inflammation, and cancer surveillance.

Here, we present a protocol that outlines the isolation, expansion, and adoptive transfer of human ILC2s from peripheral blood mononuclear cells for an in vivo lineage tracking experiment in a mouse model.

Additionally, we detail the steps involved in the adoptive transfer of human ILC2s to recipient mice bearing human liquid or solid tumors. For complete details on the use and execution of this protocol, please refer to Li et al. 1 .

论文信息

作者
Li Z、Ma R、Tang H、Caligiuri MA、Yu J
第一作者单位
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National, Medical Center, Los Angeles, CA 91010, USA; Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA 91010, USA.United States
通讯作者单位
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National, Medical Center, Los Angeles, CA 91010, USA; Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA 91010, USA; City of Hope Comprehensive Cancer Center, Los Angeles, CA 91010, USA; Department of Immuno-Oncology, City of Hope, Los Angeles, CA 91010, USA. Electronic address: jiayu@coh.org.United States
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
STAR protocols2024 Sep 20
原文标识
PubMed 39088329 · DOI 10.1016/j.xpro.2024.103096